The Ultimate Guide To Imipenem
MI-CP151 was a stage 1b randomised, double-blind, placebo managed, dose-escalation, multicentre examine to evaluate many intravenous doses of sifalimumab, in Grownup sufferers with dermatomyositis or polymyositis (NCT00533091). Major demo targets have been To guage the security and tolerability of sifalimumab in dermatomyositis or polymyositis suff